Different treatments for Crohn's disease complicated by severe acute lower gastrointestinal bleeding: infliximab therapy is critical and cannot be ignored.

Shuoyi Yao, Zheyu Wang, Mingyan Xie, Shengnan Wu, Yingjuan Feng, Xiaoming Liu, Fen Wang

Abstract read

In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuoyi Yao *Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Zheyu Wang *Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Mingyan XieDepartment of Gastroenterology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.

Shengnan WuDepartment of Gastroenterology, Yueyang Central Hospital, Yueyang, Hunan, China.

Yingjuan FengDepartment of Gastroenterology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Xiaoming LiuDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Fen WangDepartment of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Acute severe lower gastrointestinal bleeding (SLGIB) is one of the life-threatening complications of Crohn's disease (CD) whose therapy is being optimized constantly. We aim to evaluate the therapeutic efficacies and economic benefits of different treatments for acute SLGIB in CD. Method: A multicenter retrospective cohort study was conducted in Hunan Province of China on CD patients with acute SLGIB; here, we analyzed the clinical (hemostatic effects, hemoglobin improvement, rebleeding risk, anti-inflammatory influence, and complications) and economic (duration and cost of hospital stay) characteristics of infliximab, surgical, and traditional hemostatic therapies. Results: All three groups showed no obvious signs of bleeding in the first week. The negative conversion rates of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in the infliximab therapy group were significantly higher than those in the other two groups (adjusted- Conclusion: Compared to surgery and traditional therapy (such as somatostatins or octreotide), infliximab therapy could control acute SLGIB in CD as well as achieve similar improvement in hemoglobin level with additional anti-inflammatory effects and lower rebleeding risk. Furthermore, infliximab therapy was found to be more economical than surgery.

Indexed as

Crohn’s diseasehemostatic therapyinfliximablower gastrointestinal bleedingsurgery

Identifiers

PMID41808876

DOI10.3389/fphar.2026.1687439

PMCPMC12967973

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.